These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2009-016996-31 A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onse... 2012-12-18 due-trials
Not reported 2009-017904-95 Estudio abierto de extensión para evaluar la seguridad de USL255 como terapia adyuvante en pacientes con crisis de inicio parcial refractarias que habían participado en el P09-004, un estudio en fase ... 2014-03-13 due-trials
Reported results Terminated 2011-001318-32 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue T... 2017-03-20 due-trials
Reported results Terminated 2011-004109-25 An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters 2017-02-22 due-trials
Reported results 2014-003961-49 A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in t... 2016-08-26 due-trials
Exempt, with results Terminated 2015-004214-14 A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts for ... not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Upsher-Smith Laboratories, Inc. is now effectively part of Sawai Pharmaceutical .